With trauma compounding and resources stretched, could the Israel-Iran conflict accelerate the adoption of digital and AI-driven mental health care in Israel?

As Israel grapples with the psychological strain of compounded conflict, first following the October 7 Hamas attacks, and more recently with the confrontation against Iran in the wake of Operation Rising Lion, mental health resources are being stretched to their limits. Even amid the newly announced ceasefire, which is meant to offer a halt to hostilities for now, the emotional aftermath across the nation is far from resolved.

Systemic challenges like clinician shortages, access disparities, and a lingering stigma around traditional therapy stand in contrast to a growing, urgent national need for support. According to McKinsey, the total burden from mental health conditions in 2025 is estimated at 183 million disability-adjusted life years (DALYs). At the same time, “emerging therapeutic options such as digital therapies are gaining recognition for their accessibility and effectiveness, particularly in low-resource settings.”

Indeed, global online behavior reflects growing openness to and traction for such digital therapies. As highlighted by Harvard Business Review, therapy has become the leading use case for generative AI in 2025.

In Israel, a multitude of platforms are already operating in this space. These include AI-based services such as Kai.ai, physiological approaches from Calmigo, passive sensing technologies by Behavidence, and the digitally scaled trauma response of NATAL, Israel’s Trauma and Resiliency Centre.

While the current situation unfolds against the uncertainty of a ceasefire and atop over a year and a half of sustained conflict, it raises the question of whether this juncture will mark an inflection point for tech-enabled mental health care in Israel, and whether these tools will gain the trust, investment and institutional support to play a more central role.

Cracks in the system reveal a growing need for alternatives

In recent years, Israel’s mental health system has faced mounting pressure, with the current situation exposing the full extent of its strain. 

“Since October 7, we have seen an increase of 300% in people consuming psychiatric drugs in Israel,” said Adi Wallach, CEO and Co-Founder of Calmigo. “And the estimation right now is that there are 3 million people who are suffering from trauma.”

Organizations like NATAL, founded in 1998, have had to rapidly expand in response to escalating demand. In the earliest hours of October 7, it was the only helpline broadcast on Israeli television. It has also been instrumental in developing new, condensed treatment protocols adopted by both the Ministry of Health and the Ministry of Defence. 

“Before October 7, NATAL had about 100 therapists,” said Ifat Morad, Director of International Relations, Partnerships and Resource Development. “Now we have more than 600 therapists all over Israel.” In tandem, the organization has launched a new app, expanded services via WhatsApp and Zoom, and integrated an AI bot to triage helpline calls. “We had about 400 people getting therapy one on one on a weekly basis. Now we have more than 3,000 on a weekly basis and counting,” she continued.

Mental health crises in Israel are often marked by waves of people turning to NATAL’s services. Speaking to the present national climate, Morad observed: “we are now in what we call rolling trauma. The trauma didn’t just finish. It’s rolling as we speak. We’re in it, all of us.”

Startups step in with tech-driven mental health solutions

While traditional mental health services in Israel have worked to leverage digitisation to expand their reach, several startups are aiming to address the growing mental health crisis with tech-first or hybrid solutions.

Kai.ai, a hybrid mental health platform combining human clinicians with conversation-based AI, has reached over 200,000 people in need. Initially launched in English, the service expanded to Ukrainian and Russian during the Ukraine war, and to Hebrew following October 7. In partnership with the humanitarian organization The Joint, Kai began offering free support to reservists, students, and civilians – a move it has continued amid the Israel-Iran conflict, now providing a full month of subsidized support to anyone impacted. The offer remains in place, notwithstanding the ceasefire.

For CEO Alex Frenkel, the AI component is central to the platform’s mission “because the AI is accessible 24/7.”

Calmigo, meanwhile, takes a physiological approach, offering a handheld device that activates the parasympathetic nervous system to deliver both immediate relief and long-term support. “You can think about the device as a remote control to your nervous system,” explained Wallach, who noted that Calmigo is one of the only non-medicated solutions providing fast-acting relief alongside sustained therapeutic benefits. “It’s as easy to use and as effective as a pill, but does not require a prescriber, and at a fraction of the cost as well.” Following October 7, the company donated 1,300 units to hostage families, soldiers, and traumatised children.

Behavidence was founded to bridge the gap in early diagnostics and intervention. “We detect mental health disorders or dynamics based on how you use your phone,” said Co-Founder Roy Cohen. “Just by passively sensing your patterns of behaviour.”

The passive approach, he explained, is key to long-term user retention. “We chose passive sensing because whenever we ask the user to do something, the chances of them staying with us a week later is gone.”

In the wake of October 7, the company also made its product freely available to support those affected. It is now working with HMOs and the Ministry of Defense to monitor PTSD symptoms in reservists.

For Cohen, the fundamental inefficiency in how care is delivered is a costly blind spot: “Treating early is cheap. But now the systems are designed to treat only when the symptoms are severe.”

Israeli eye surgery robotics company ForSight Robotics has raised $125 million in a Series B round led by Eclipse. The funding will be used to advance development of the company’s ORYOM platform, a robotic system designed to perform cataract surgery and treat other common eye diseases. The system aims to deliver more precise procedures, expand access to quality care, and reduce the physical burden on surgeons. ForSight’s first human clinical trials are expected to begin this year.

Founded in 2020 by Prof. Moshe Shoham, Dr. Daniel Glozman, and Dr. Joseph Nathan, ForSight is currently headquartered in Yokneam Illit and will soon relocate to Caesarea. The company has raised $195 million to date and employs 110 people in Israel.

In addition to Eclipse, the round included investment from a strategic corporate partner, Dr. Fred Moll, who is widely regarded as the “father of surgical robotics,” India’s Adani Group, Reiya Ventures, and other existing backers. The company has already conducted hundreds of successful preclinical procedures in animal trials and will soon begin robotic cataract surgeries in humans.

“We finalized the round while missiles were flying into Israel. Twenty percent of our team is in the reserves, we support them and their families deeply,” Natahn told Calcalist. “We’ve faced COVID, economic crises, and now war. Still, we secured backing from some of Silicon Valley’s largest funds in both our Series A and B. Our uniqueness is stronger than the challenges around us.”

Dr. Nathan emphasized that the round represents a strong vote of confidence from a key industry player “A strategic company in our space invested a substantial amount, but entered only as a financial partner, I’m not tied to them strategically. All funds go to the company and are not contingent on milestones.”

The new capital will help ForSight move through regulatory pathways, launch U.S. operations, and prepare for commercialisation. “I believe we’ll reach the market in the coming years once we secure all FDA approvals,” said Nathan.

“There’s no existing robotic solution in ophthalmology. We are reengineering eye surgery. Instead of a surgeon manually operating tools, they’ll sit at a console and guide robots to perform the procedure with far greater precision and comfort. Surgeons will be able to do more procedures with better ergonomics. Today, 66% of ophthalmic surgeons suffer from spinal injuries due to physical strain, our platform helps solve that.”

From a patient’s perspective, he added, “They know they’re getting the highest quality care.”

The global vision crisis, affecting over one billion people with preventable vision impairment and avoidable blindness, is exacerbated by a limited and declining ophthalmologist workforce. Worldwide, there are only 31.7 ophthalmologists and 14.1 cataract surgeons per million people. By 2035, the number of practicing ophthalmologists is expected to decline by 12%, while demand for eye care is projected to rise by 24%. Simultaneously, more than 600 million people suffer from cataracts, yet only 30 million receive surgical treatment. In the United States alone, just four million cataract surgeries are performed annually, underscoring the significant gap between patient need and available surgical capacity.

The ORYOM platform is designed to deliver highly precise and consistent ophthalmic procedures, starting with cataract surgery. Leveraging AI-based algorithms, advanced computer vision, and micro-mechanics, the robotic system offers exceptional dexterity and manoeuvrability, while also improving the surgeon’s ergonomic experience.

“Cataracts are part of aging, and rates are rising with obesity and diabetes. But many surgeons are retiring, and there’s not enough new talent entering the field,” Nathan noted. “This gap will only grow.”

Dr. Nathan calls the Series B one of the largest medical funding rounds in Israel in recent years, an exceptional feat in a turbulent time.

“We see ophthalmology as the next frontier in medical robotics, just like general surgery was before Intuitive Surgical revolutionized it with the da Vinci system. It’s a massive market with urgent global need.”

The company’s advisory board includes Dr. Fred Moll, the founder of Intuitive Surgical and the da Vinci surgical system, and Mr. Rony Abovitz, the founder of MAKO Surgical Corp. Dr. Fred Moll recently joined the company’s board of directors. Additionally, ForSight Robotics benefits from the expertise of a world-class clinical advisory board that includes Dr. David Chang, Dr. Vance Thompson, Prof. Boris Malyugin, Dr. Sam Garg, and Dr. Modi Naftali.

Israeli health tech startup NeuroKaire, Cofounded by Dr. Daphna Laifenfeld who has a PhD in Medical Science and Molecular Biology from Technion, has rolled out a blood test in the US and Israel that they say can measure the responsiveness of a patient with major depressive disorder to common antidepressants.

This week, NeuroKaine have rolled out a blood test in the US and Israel that they say can measure the responsiveness of a patient with major depressive disorder to common antidepressants.

NeuroKaire says its novel, AI-assisted tech uses stem cells to create a brain proxy against which drugs can be tested to find the best one.

Depression is one of the most common forms of mental disorder, affecting more than 330 million people worldwide. Treatment methods rely primarily on a taxing trial-and-error process to find the right prescription drug, which can take years.

In Israel, the psychological toll of 23 months of war and counting has made the need for effective mental health treatment felt more than ever.

The blood test, promises to create a platform for personalised treatment of mental disorders. Guided by the test results, clinicians and psychiatrists can determine which treatment is most suited to a particular patient’s condition.

“For far too long, patients with clinical depression have endured a grueling trial-and-error process before finding an effective treatment,” Cohen Solal told The Times of Israel. “Around one-third of the time, a patient improves or recovers from depression when seeking treatment, and around two-thirds of the time, physicians will need to change their medication or dosage multiple times.”

“Typically, the guessing game of identifying the right drug for a patient with clinical depression can take between 12 to 18 months. We are bringing that down to two months,” she claimed.

The blood test began being offered in Israel and the US this week, though the new technology still needs more research and trial data to determine its effectiveness, according to Prof. Mark Weiser, who heads the Psychiatry Department at Sheba Medical Centre.

“NeuroKaire’s unique combination of stem-cell technology, genomics, and AI represents an evolutionary step forward from traditional pharmacogenetics and is promising, but more research needs to be done in large clinical trials with hundreds of patients, comparing the outcomes with those that haven’t taken the test, and further improve results for patients,” Weiser said.

NeuroKaire’s blood-based screening tool, BrightKaire, was recently granted laboratory-developed test regulatory approval from the Centers for Medicare & Medicaid Services in the US, making it the first clinically deployed test based on neurons derived from blood, the startup said.

Cohen Solal and Laifenfeld have decades of academic expertise in brain research and personalised medicine between them. Cohen Solal spent a decade studying psychiatric disorders at Oxford University, University College London and Columbia University. Laifenfeld has worked in brain research at the Technion and Harvard University, and has over 20 years of experience in personalised medicine, including serving as head of precision medicine at Teva Pharmaceuticals Industries.

The two neuroscientists met when Cohen Solal immigrated from the US to Israel in 2017, and they decided to join forces to found NeuroKaire in 2018. The two shared a vision to develop a more precise personalised test that clinicians could use in order to pick the optimal drug therapy for patients with clinical depression.

NeuroKaire’s R&D team then turns the stem cells into frontal brain neurons — the brain region most implicated in mental illness and depression — and tests them against 70 different antidepressants, helping to pinpoint the most effective drug or combination therapy for each patient.

Using a proprietary AI platform to analyse personalised data, including a patient’s genetic data, medical history, and microscopic neuronal imaging, the test produces a report detailing the patient’s response to different medications, including the likelihood of side effects.

“Depression is reduced connectivity in the brain, often expressed in a lack of motivation,” Cohen Solal explained. “With our brain in a dish platform, we have a window into the brain and can analyze how well those neurons are connecting or communicating after exposure to antidepressants, and we turn that into a quantitative readout for how strongly a drug has affected connectivity in those samples.”

“Our brain in a dish technology tells you not just if the drug gets past the liver to the brain, but what it does in the brain and whether it works,” Cohen Solal noted.

Cohen Solal said that the startup has validated the technology in clinical trials of the blood-based diagnostic in Israel in collaboration with Sheba Medical Center in Ramat Gan and Geha Mental Health Center in Petah Tikva. In the US, trials were conducted at Jefferson Hospital in Philadelphia and in collaboration with the National Institute of Mental Health. In addition, NeuroKaire has formed partnerships with Israeli biotech companies Clexio and Neurosense.

“In the past two decades, our knowledge of human genetics and brain biology has advanced at an unprecedented pace, but it is still limited,” said Weiser. “The underlying problem is that when a patient comes for treatment, there is no test based on biology as to whether I should prescribe Prozac or a different antidepressant, but it is based on consultation and clinical impressions.”

Weiser said other companies that have developed blood tests based on genes to determine the best drug treatment for depression, were not well-validated.

In 2023, NeuroKaire expanded to the US and opened a commercial lab, while its R&D center, employing 25 people, is based in Tel Aviv. To date, the startup has raised $25 million from venture capital investors, including GreyBird Ventures, Meron Capital, Jumpspeed Venture Partners and Sapir Ventures.

“Israel has fantastic life sciences and neuroscience PhDs, which is wonderful for hiring great R&D scientists,” Cohen Solal said. “It’s a mission of ours because of Israel and because of the war to launch this test here as well, and we are very happy to be able to help in this time of need.”

A report published by the State Comptroller’s Office earlier this year found that approximately 3 million Israeli adults may suffer from post-traumatic stress disorder, depression, or anxiety as a direct consequence of the events of the October 7, 2023, Hamas-led massacre in southern Israel and subsequent war in Gaza.

“Many of the drugs overlap for depression and PTSD,” said Cohen Solal. “Physicians can use our technology to help them choose between PTSD medications as well.”

“But in the future, we will specifically be recruiting cohorts of PTSD patients so we can validate it as well in the PTSD setting,” she added.

Cohen Solal said that depression is the first indication, but going forward, tests for other neurological conditions are being planned using the same method.

“NeuroKaire’s mission is to bring precision medicine to the brain,” said Cohen Solal. “Next year, we will be starting our studies in ADHD. That’s going to be our next indication.”

Against the backdrop of a worrying rise in antisemitism on campuses worldwide, the Technion is offering international students a safe, supportive, and academically world-class alternative

The Technion opened a new program for international students developed in response to waves of antisemitism on campuses in the U.S. and Europe. The program is the Technion’s first such initiative and aims to attract talented young people from around the world and integrate them into the Israeli academic community.

“Antisemitism in Canada is soaring – it’s worse than it looks,” said Anna Durov, a 19-year-old student from Canada. “I had already been accepted to a mathematics program at the University of Toronto, but because of reports of antisemitism at the university, I preferred to study at the Technion.”

Students in the program will receive extensive support, including housing, social mentors, team-building activities, and academic assistance, to ensure a smooth transition and full integration into campus life and studies. “It feels almost unreal,” shared Yael Cowly, 18, from Barcelona. “I registered immediately. I’ve heard so much about the Technion, and I know it’s considered the ‘MIT of Israel.’”

The first cohort includes 26 students from eight countries: the United States, Brazil, Russia, Canada, Spain, Germany, Azerbaijan, and Israel. They will take English-taught foundation courses in mathematics, science, and engineering, along with an intensive Hebrew ulpan, enabling them to join regular faculty tracks in their second year.

“Thanks to the program, I can study in English with my group during the first year while improving my Hebrew in the ulpan,” added Anna. “It makes continuing my studies easier and creates a supportive community.”

The students will participate in orientation and preparatory courses in mathematics, chemistry, and physics until the Technion’s academic year begins in October 2025. Later, they will choose from degree programs in eight Technion faculties: Mechanical Engineering, Aerospace Engineering, Chemical Engineering, Civil and Environmental Engineering, Biotechnology and Food Engineering, Materials Science and Engineering, Chemistry, and Biology.

“I still don’t know what I’m going to study, and that’s the beauty of the program – it keeps my options open and lets me explore first,” said Gabriel Takeuchi from Brazil, who has already been in Israel for a while and even found love here. “For me, learning Hebrew is a big bonus – it means I’ll be able to talk to my girlfriend’s grandparents at Friday night dinners.”

The Technion sees it as an opportunity to offer Jewish and international students a safe, advanced, and welcoming academic environment. “There’s a wave of antisemitism right now in Barcelona, and I definitely feel safer here – and I want to contribute to the country,” said Yael. “I’m in the Academic Reserve track, and after I finish my degree, I want to enlist.”

“This program opens a new path for outstanding students from all over the world to earn their undergraduate degree at the Technion, a leading institution in engineering and science, and in doing so gives Israel a new generation of graduates connected to Israeli academia and society,” said Emma Afterman, director of the Technion International School. “The program enables students to quickly learn Hebrew and join regular faculty programs from their second year. It’s the first initiative of its kind at the Technion, and we are thrilled to welcome our first cohort.”

Technion President Prof. Uri Sivan said: “This new program is our response to the rising antisemitism on campuses in North America, Australia, and Europe. The Technion, which opened its doors a quarter of a century before the State of Israel was established, was founded, among other reasons, to serve as a refuge for those who felt threatened abroad. In this spirit, already in November 2023, with the outbreak of protests around the world, we opened the Technion to visiting students and researchers from abroad, inviting them to benefit from the supportive environment we provide for their studies and research. The new program offers a framework for undergraduates who wish to study on a welcoming campus free of antisemitism and hate. The young people who come to us from around the world are a testament to the Technion’s scientific and engineering excellence and its international standing as one of the world’s leading technological universities. I am excited to welcome our new students and wish them great enjoyment and success in their studies.”

The Carasso and Hecht Centre’s will drive innovation, research, and industry collaboration in food production and biotechnology

These new centre’s established at the Technion, will promote education, research, and innovation in the food sector and strengthen the connection between the Technion and the entire food industry, from traditional to cutting-edge.

Eliminating hunger and improving food security are among the major challenges facing humanity in the 21st century, as defined by the United Nations’ Sustainable Development Goals. The Technion houses the only faculty in Israel dedicated to food engineering, leading the Israeli food-tech industry.

Dean of the Faculty of Biotechnology and Food Engineering, Prof. Esty Segal, added, “As dean, I see the establishment of these two centre’s as a clear manifestation of our vision—to position the Technion and the State of Israel at the global forefront of innovation in food. This field is not only an industrial growth engine—it is a profound scientific, environmental, and social challenge, integrating biotechnology, engineering, health, life sciences, and sustainability. Both centre’s were born out of a multidisciplinary pursuit of excellence, enabling us to develop breakthrough technologies, bridge basic and applied research, and lead food solutions for a world facing climate change, nutritional inequality, and resource depletion. It is also a commitment to Israel’s future, ensuring food security, advancing sustainability, and training the next generation of visionary, bold, and responsible scientists and engineers. This is a powerful link between science and purpose, between knowledge and impact—for Israel and the entire world.”

The new centre will support the Technion and the faculty in their mission—to bridge science, engineering, and technology in shaping the future of food production, preservation, and consumption, while advancing key goals such as waste reduction and environmental protection. We face major research challenges that intertwine health, sustainability, and innovation, alongside the educational task of training the next generation of scientists and engineers. This center will allow Technion researchers to translate ideas into real-world impact. We thank the Carasso family across generations, including the younger generation, for enabling the establishment of this important center. Let us celebrate this milestone—and now, to work.”

The Carasso family’s contribution, which will strengthen Israel’s footprint in global food research, is intended to support and realize their values and those of their company, emphasizing Zionism, excellence in science education, reducing disparities, and investing in infrastructure. The upgraded, expanded facility will be unique in Israel and among the most advanced in the world. It will include a research and development center for industrial-scale production, equipment for scaling lab processes to pilot scale, laboratories for food and biomaterials analysis, a fermentation lab, an industrial kitchen, and a tasting room—all designed to support teaching, research, and collaboration with industry and startups.

The Esther and Herbert Hecht Sustainable Protein Research Center is a multidisciplinary center that brings together approximately 50 researchers from various Technion faculties to develop food solutions for a better future. The center will serve as a model for sustainable protein research, promote collaborations within and beyond the Technion, and foster innovation, entrepreneurship, and the training of professionals in this field.

The centre is the world’s first academic centre in this field. Its vision is to serve as a multidisciplinary hub for researching and developing sustainable sources of protein. Its activities are grounded in Technion excellence and the rapid global development of this field. The center promotes research, attracts outstanding new researchers, trains graduate and postdoctoral students, and provides cutting-edge research infrastructure. It offers competitive research grants to launch initial interdisciplinary projects and holds conferences to strengthen connections between relevant researchers at the Technion and beyond.

Pitch Night isn’t just a student competition — it’s a launchpad for the next generation of Technion innovators. By turning bold ideas into real-world solutions, these students are gaining hands-on experience in entrepreneurship, engineering, and impact. It’s a powerful glimpse into how the Technion is shaping Israel’s future, and the future of technology itself. Keep scrolling to see what innovation in action really looks like.

I think there’s something entrepreneurial in Israeli DNA. I feel beyond privileged to have listened to all the wonderful pitches tonight and hopefully follow up with them.” – ERIC BRANDON, STARTUP BUSINESS DEVELOPMENT

On June 18, 2025, Pitch Night brought together food, networking, and fierce innovation as Technion t:hub students took the stage to present the next generation of Israeli startups. From AI to sustainable solutions, each team unveiled their business plans, elevator pitches, and bold visions for the future.

An esteemed panel of investors and entrepreneurs challenged the students on everything from scalability to go-to-market strategy, culminating in the selection of a standout winner: Omer Sabary, whose pitch left the judges and audience inspired.

Whether you’re passionate about Israel, technology, or the future of global innovation, Pitch Night offered a front-row seat to what’s next from Startup Nation.

The crew of the cargo ship Eternity C could hardly believe their eyes – within minutes, their vessel was sunk in broad daylight in the Red Sea by an unmanned boat and RPG missiles, and they were taken captive by Houthi rebels. The next day, another container ship was attacked in the Red Sea – and it too was sunk. Just a few years ago, such a scenario would have sounded completely far-fetched. Yet these two alarming incidents occurred just this past month – and they are not the only ones. Worse still – they are only part of a growing wave of threats to the global supply chain, driving up the costs of production, transport, and logistics.

In recent years, the global supply chain has been severely shaken by a series of crises and events: the COVID-19 pandemic, the war in Ukraine, the Houthi attacks on the maritime route through which approximately 50% of global goods once passed, and the latest disruptive development – the U.S. administration’s new tariff policies.

Pickommerce CTO Amir Shapiro and Cybord Founder and CTO Eyal Weiss and CEO Oshri Cohen are both Technion alumni.

By all appearances, Decart is moving fast. The Tel Aviv-based AI startup has secured $100 million in new funding at a $3.1 billion valuation, just two years after it was founded. It now counts 60 employees and a growing global presence. At the center of its pitch: the belief that AI’s next frontier won’t be text or images, but real-time video.

While others rushed to build language models, Decart started with the hardware layer, developing a GPU optimization stack that it quietly licensed to major cloud providers in multi-million dollar deals. That foundation gave the company early revenue, and the technical leverage to go further.

Today, Decart’s flagship models Oasis and Mirage aim to do something few others have achieved: generate and manipulate video on the fly. Oasis, which the company says is the first real-time video generation model launched at scale, attracted a million users within days of release. Mirage, its newest tool, lets users modify live video streams with text prompts, tailored for use cases like streaming and gaming.

Decart CEO Dean Leitersdorf is a Technion alumnus.

Michael Belkin is a serial entrepreneur of a particularly rare breed. Like other serial entrepreneurs, he never stopped developing, researching, and inventing throughout his life, but he did so not out of a pursuit of money, but primarily out of the joy of creation, curiosity, and a desire to bring medicine to the world. It so happened that he made his first exit when he was already 68 years old. At an age when most of his peers were retiring, Belkin sold a company he founded for $180 million. Even then, he had no intention of retiring, but continued to research and invent. Last year, when he was 82, the second exit came: one of his greatest inventions, an automated device for treating glaucoma, was sold for $466 million to the eye care giant Alcon.

And there’s still no talk of rest. Every morning, as he has for 30 years, Belkin shows up at the same office at the Eye Research Institute at Sheba Medical Center, turns on the fluorescent light above him, and begins his workday in a space that looks like a small museum. The room is packed with compact binders, framed certificates, photos, posters of organs of vision, and medical models collected over decades. It perfectly suits his image as a professor of ophthalmology at Tel Aviv University who has authored more than 500 scientific articles and holds over 40 patents.

In a year marked by war, political upheaval, and global economic volatility, Israel’s tech sector continues to defy the odds — and the Technion is once again at the heart of its resilience. Three of the standout companies on Calcalist’s 2025 list of the 50 most promising Israeli startups — Decart, ForSight Robotics, and OX Security — all trace their roots to the Technion, where bold ideas and deep scientific training are shaping real-world solutions. These startups aren’t just succeeding; they’re changing the game across AI, healthcare, and cybersecurity.

Decart: Accelerating the Generative AI Revolution

Just 18 months after its founding, Decart has raised $53 million, earned a half-billion-dollar valuation, and captured the attention of top-tier venture firms like Sequoia Capital and Benchmark. At its core is a powerful systems-level AI infrastructure that enables a tenfold improvement in training and inference speed for large generative models, unlocking real-time AI applications previously limited to tech giants.

The company’s momentum is fueled by deep academic and technical foundations. Technion alumnus Dean Leitersdorf, Decart’s CEO and co-founder, launched the company with fellow co-founder Moshe Sason during a period of reserve duty — building their team and vision under extraordinary pressure. Their platform dramatically reduces the resource load of generative AI, allowing them to train and deploy their own foundational models. It’s a leap forward in making powerful AI not only faster and cheaper, but more accessible to companies and creators around the world.

ForSight Robotics: Precision Eye Surgery for a World in Need

More than 2 billion people worldwide suffer from vision impairment, but there aren’t nearly enough trained eye surgeons to meet the growing demand. ForSight Robotics aims to bridge that gap with a robotic microsurgery platform that delivers 10x the accuracy of a human hand. Their technology integrates robotics, machine learning, and computer imaging to perform delicate eye procedures with unprecedented precision, starting with cataract surgery.

The company was co-founded by Technion alumnus and company President and Chief Medical Officer Dr. Joseph Nathan. A practicing ophthalmologist and engineer, Dr. Nathan helped launch ForSight alongside Technion Professor Moshe Shoham, a pioneer in medical robotics and founder of Mazor Robotics. Together with CEO Dr. Daniel Glozman, they’ve built a platform with the potential to democratize surgical care, especially in regions with limited access to specialists. With the world’s aging population and rising chronic disease rates, ForSight’s mission is not just to enhance surgical performance, but to make sight-saving procedures globally scalable.

OX Security: Cutting Through the Noise in Cyber Defence

In today’s cybersecurity landscape, overwhelmed teams are bombarded with alerts — many of them low-risk. OX Security takes a radically different approach, focusing only on the small percentage of vulnerabilities that could truly cripple a business. That philosophy, born in the wake of the SolarWinds hack, has resonated strongly with customers and investors alike. Since emerging from stealth in 2022 with a $34 million Seed round — one of the largest in Israeli cybersecurity history — OX Security has quickly amassed hundreds of paying clients.

The company was founded by Technion alumnus Neatsun Ziv, former VP of Threat Prevention at Check Point, alongside CPO Lior Arzi. Both are Unit 8200 veterans and cybersecurity experts with decades of combined experience. Their mission is to cut through the noise, reduce alert fatigue, and help organizations defend themselves more effectively against the threats that truly matter. With most of its early competitors already acquired, OX Security is now a standout in a space that demands clarity, speed, and precision.

Together, Decart, ForSight Robotics, and OX Security reflect the Technion’s role as a launchpad for ideas that matter — and for startups built not just to survive disruption, but to lead through it.